Adalimumab, etanercept, golimumab or infliximab (DrugBank: Etanercept, Adalimumab, Infliximab, Golimumab)
15 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
15 | Inclusion body myositis | 0 |
28 | Systemic amyloidosis | 0 |
35 | Pemphigus | 0 |
38 | Stevens-Johnson syndrome | 0 |
39 | Toxic epidermal necrolysis | 0 |
46 | Malignant rheumatoid arthritis | 0 |
50 | Dermatomyositis | 0 |
53 | Sjogren syndrome | 0 |
56 | Behcet disease | 0 |
60 | Aplastic anemia | 0 |
85 | Idiopathic interstitial pneumonia | 0 |
228 | Bronchiolitis obliterans | 0 |
271 | Ankylosing spondylitis | 1 |
285 | Fanconi anemia | 0 |
298 | Hereditary pancreatitis | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01610947 (ClinicalTrials.gov) | May 14, 2012 | 24/5/2012 | Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease Activity | Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease Activity: a Randomized Controlled Trial | Spondyloarthritis | Drug: Adalimumab, Etanercept, Golimumab or infliximab | University Hospital, Montpellier | NULL | Completed | 18 Years | N/A | All | 398 | N/A | France |